lapatinib + vinorelbine

Lapatinib + vinorelbine is a combination therapy used primarily for the treatment of metastatic HER2-positive breast cancer, particularly in patients who have previously received other treatments. Lapatinib is a small molecule tyrosine kinase inhibitor that targets the intracellular domains of both epidermal growth factor receptor (EGFR/HER1/ERBB1) and human epidermal growth factor receptor 2 (HER2/ERBB2), thereby inhibiting tumor cell proliferation driven by these receptors[8]. Vinorelbine is a semi-synthetic vinca alkaloid that disrupts microtubule formation by binding to tubulin, leading to mitotic arrest and apoptosis in rapidly dividing cells[6]. The combination has demonstrated efficacy and manageable toxicity profiles in phase I/II clinical trials, offering an all-oral regimen option for patients with HER2-positive metastatic breast cancer who may have been heavily pretreated[1][3][4][5].

Brand names

TykerbNavelbine

Other names

lapatinib + vinorelbine